|
关注：1
2013-05-23 12:21
求翻译：As part of study eligibility requirements, subjects must test positive for a sensitizing EGFR mutation (either exon 19 deletion or exon 21 [L858R] substitution mutation) to determine eligibility for treatment with erlotinib. This may occur in parallel with study screening assessments, provided that an IRB-approved ICF 是什么意思？ 待解决
 悬赏分：1
- 离问题结束还有
As part of study eligibility requirements, subjects must test positive for a sensitizing EGFR mutation (either exon 19 deletion or exon 21 [L858R] substitution mutation) to determine eligibility for treatment with erlotinib. This may occur in parallel with study screening assessments, provided that an IRB-approved ICF
问题补充： |
湖北省互联网违法和不良信息举报平台 | 网上有害信息举报专区 | 电信诈骗举报专区 | 涉历史虚无主义有害信息举报专区 | 涉企侵权举报专区
